Ura T - Search Results

1

Current Vaccine Platforms in Enhancing T-Cell Response.

Ura T, Takeuchi M, Kawagoe T, Mizuki N, Okuda K, Shimada M. Ura T, et al. Vaccines (Basel). 2022 Aug 21;10(8):1367. doi: 10.3390/vaccines10081367. Vaccines (Basel). 2022. PMID: 36016254 Free PMC article. Review.

2

Developments in Viral Vector-Based Vaccines.

Ura T, Okuda K, Shimada M. Ura T, et al. Vaccines (Basel). 2014 Jul 29;2(3):624-41. doi: 10.3390/vaccines2030624. Vaccines (Basel). 2014. PMID: 26344749 Free PMC article. Review.

3

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.

Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. Ura T, et al. Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24. Vaccine. 2021. PMID: 33279318 Free PMC article. Review.

4

Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles.

Ito S, Nakamura J, Fukuta M, Ura T, Teshigawara T, Fukushima J, Mizuki N, Okuda K, Shimada M. Ito S, et al. Among authors: ura t. Vaccine. 2021 May 27;39(23):3152-3160. doi: 10.1016/j.vaccine.2021.04.035. Epub 2021 Apr 30. Vaccine. 2021. PMID: 33934918

5

Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.

Shimada M, Wang H, Ichino M, Ura T, Mizuki N, Okuda K. Shimada M, et al. Among authors: ura t. Gene Ther. 2022 Nov;29(10-11):636-642. doi: 10.1038/s41434-021-00308-z. Epub 2022 Jan 6. Gene Ther. 2022. PMID: 34987192

6

Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

Abe S, Okuda K, Ura T, Kondo A, Yoshida A, Yoshizaki S, Mizuguchi H, Klinman D, Shimada M. Abe S, et al. Among authors: ura t. J Gene Med. 2009 Jul;11(7):570-9. doi: 10.1002/jgm.1332. J Gene Med. 2009. PMID: 19391169 Free PMC article.

7

Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.

Ura T, Yoshida A, Xin KQ, Yoshizaki S, Yashima S, Abe S, Mizuguchi H, Okuda K. Ura T, et al. J Gene Med. 2009 Feb;11(2):139-49. doi: 10.1002/jgm.1277. J Gene Med. 2009. PMID: 19065543

8

Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

Shimada M, Wang HB, Kondo A, Xu XP, Yoshida A, Shinoda K, Ura T, Mizuguchi H, Klinman D, Luo JL, Bai H, Okuda K. Shimada M, et al. Among authors: ura t. Gene Ther. 2009 Feb;16(2):218-28. doi: 10.1038/gt.2008.152. Epub 2008 Oct 16. Gene Ther. 2009. PMID: 18923453 Free PMC article.

9

Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy.

Yasuda T, Ura T, Taniguchi M, Yoshida H. Yasuda T, et al. Among authors: ura t. PLoS One. 2016 Dec 14;11(12):e0167952. doi: 10.1371/journal.pone.0167952. eCollection 2016. PLoS One. 2016. PMID: 27973543 Free PMC article.

10

Actin network formation by unidirectional polycation diffusion.

Kwon HJ, Kakugo A, Ura T, Okajima T, Tanaka Y, Furukawa H, Osada Y, Gong JP. Kwon HJ, et al. Among authors: ura t. Langmuir. 2007 May 22;23(11):6257-62. doi: 10.1021/la063416k. Epub 2007 Apr 27. Langmuir. 2007. PMID: 17461601

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page